Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) Director Kim Tsuchimoto sold 4,090 shares of the company’s stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the sale, the director directly owned 7,396 shares in the company, valued at $823,840.44. This trade represents a 35.61% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Monopar Therapeutics Stock Down 1.8%
Shares of MNPR stock opened at $111.89 on Friday. The stock has a market cap of $750.78 million, a P/E ratio of -51.56 and a beta of 1.47. Monopar Therapeutics Inc. has a fifty-two week low of $32.77 and a fifty-two week high of $124.82. The business has a fifty day simple moving average of $106.44 and a 200-day simple moving average of $75.00.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.64) by $0.02. On average, sell-side analysts anticipate that Monopar Therapeutics Inc. will post -2.94 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
MNPR has been the topic of several research reports. Cantor Fitzgerald lowered shares of Monopar Therapeutics from an “overweight” rating to a “neutral” rating and increased their price target for the company from $109.00 to $119.00 in a research report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Friday, July 17th. Piper Sandler set a $105.00 target price on Monopar Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright increased their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Finally, UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $118.67.
Read Our Latest Research Report on Monopar Therapeutics
About Monopar Therapeutics
Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.
The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.
Read More
- Five stocks we like better than Monopar Therapeutics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
